Sign inJoin waitlistJoin the waitlist

Gheath Al-Atrash

Associate Professor, Stem Cell Transplantation & Cellular Therapy · University of Texas M D Anderson Cancer Center

Credentials: · · · · ·

History

University of Texas M D Anderson Cancer Center
Present
University of Texas M D Anderson Cancer Center
Present

Hematology and Medical Oncology
University of Texas M D Anderson Cancer Center
2007–2008
Internal Medicine
2002–2005
Texas Coll of Osteopathic Med
1998–2002

Research

PD-L1 expression in triple-negative breast cancer
Cancer Immunology Research · 2014 · Last of 17 authors · 1,143 citations
An inhibitor of oxidative phosphorylation exploits cancer vulnerability
Nature Medicine · 2018 · 800 citations
The distribution of T-cell subsets and the expression of immune checkpoint receptors and ligands in patients with newly diagnosed and relapsed acute myeloid leukemia
Cancer · 2019 · 275 citations

Richard Champlin
54 papers
Elizabeth Shpall
52 papers
Uday Popat
50 papers
Jeffrey Molldrem
44 papers
Betul Oran
40 papers
Partow Kebriaei
40 papers
Amin Alousi
39 papers
Chitra Hosing
33 papers
Issa Khouri
30 papers
Muzaffar Qazilbash
29 papers
Rohtesh Mehta
28 papers
Qaiser Bashir
27 papers

Grants

MD Anderson Cancer Immune Monitoring and Analysis Center MDA-CIMAC
National Cancer Institute · U24
PI · $16.7M · University of Tx Md Anderson Can Ctr
2017–2028
Enhancing CAR T Cell Homing Through Glycoengineering
National Cancer Institute · R21
Contact PI · $407.1K · University of Tx Md Anderson Can Ctr
2023–2026
Mitigating High Grade Radiation-Induced Lymphopenia Through Pretreatment Autologous Lymphocyte Infusion
National Cancer Institute · R21
PI · $387.6K · University of Tx Md Anderson Can Ctr
2019–2024

Clinical trials

2018-0674 - IL-7 for T-Cell Recovery Post Haplo and CB Transplant - Phase I/II
Principal investigator · Completed · Phase 1, Phase 2
M.D. Anderson Cancer Center
2020–2023
ALI Post Radiation Therapy in Patients With Lung and Esophageal Canter
Principal investigator · Terminated · Phase 2
M.D. Anderson Cancer Center
2020–2025
Nivolumab and Ipilimumab After Donor Stem Cell Transplant in Treating Patients With High Risk Refractory or Relapsed Acute Myeloid Leukemia or Myelodysplastic Syndrome
Principal investigator · Completed · Phase 1
M.D. Anderson Cancer Center
2018–2024